Byotrol announces deal will global biocidal player
CHESHIRE-based anti-microbial company Byotrol has signed an agreement to develop and commercialise biocidal products with the listed international chemical group Solvay SA.
As part of the agreement Solvay will be making a significant investment in Daresbury-headquartered Byotrol’s technical cost base in the current financial year.
Assuming normal trading conditions prevail, the board expects the Company to report EBITDA break-even in the six months to March 31 2016.
The deal formalises an already close technical relationship between the company and Solvay’s subsidiary Solvay Novecare, which claims to be a world leder in specialty polymers and surfactants with an annual turnover in excess of £3bn.
It is built upon the joint development of anti-microbials, combining the best of Byotrol’s long-lasting anti-microbial formulations and Solvay’s polymer and surfactant technologies.
AIM-listed Byotrol has already completed and patented one such product for the EU consumer market and is actively marketing it jointly with Solvay to customers.
Chief executive David Traynor said: “We have been working closely with Solvay for some time now and are delighted to formalise our existing relationship, securing a strong endorsement of our technology and development team from a world-class partner.
“We will benefit greatly from Solvay’s technical, regulatory and commercial abilities, as well of course from its global sales reach. This agreement should be a clear inflection point in Byotrol’s growth.”
Global vice president of Solvay Thierry Sclapari added: “We see a big opportunity for our unique polymer technologies in Byotrol’s anti-microbial systems. We look forward to taking our jointly-developed products to our customers worldwide.”
